- unable to take oral medication - pregnant or breastfeeding - on non-invasive positive pressure ventilation or mechanical ventilation at time of study entry - requiring ≥6l oxygen or respiratory rate ≥30 - taking bicalutamide, any systemic hormonal therapy, or prophylactic treatment for covid-19 within one month of study entry - known hypersensitivity to bicalutamide or its components. - a past medical history of cirrhosis or ast/alt/alk phos/bilirubin > 3x the upper limit of normal - patients with a clinical history of myocardial infarction or congestive heart failure within 6 months, or with prior echocardiogram showing ejection fraction < 40% - patients currently on coumadin anticoagulants due to the potential for drug-drug interactions.

- unable to take oral medication - pregnant or breastfeeding - on non-invasive positive pressure ventilation or mechanical ventilation at time of study entry - requiring ≥6l oxygen or respiratory rate ≥30 - taking bicalutamide, any systemic hormonal therapy, or prophylactic treatment for covid-19 within one month of study entry - known hypersensitivity to bicalutamide or its components. - a past medical history of cirrhosis or ast/alt/alk phos/bilirubin > 3x the upper limit of normal - patients with a clinical history of myocardial infarction or congestive heart failure within 6 months, or with prior echocardiogram showing ejection fraction < 40% - patients currently on coumadin anticoagulants due to the potential for drug-drug interactions.